Corrigendum to ‘MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway’ [EBioMedicine 46 (2019) 66–78]

After collating the data following publication of this Research Paper, the authors found that in the tumor formation experiment of nude mice in Fig. 9a, due to the irregular arrangement after taking pictures, Blank and mimic groups misplaced the tumor pictures.

Fig. 9.

Upregulation of miR-134 prevents tumour growth, MLD, and LNM of ESCC. Nude mice were injected with ESCC cells transfected with miR-134 expression and/or si-PLXNA1. (a) the tumour volume in mice; (b) the tumour weight in mice; (c) MLD in mice; (d) LM in mice. *p < .05 vs. the blank and NC groups (nude mice injected with cells without transfection and transfected with empty plasmid, respectively). Measurement data were expressed as mean value ± standard deviation. The differences in tumour volume were analysed by repeated measures ANOVA; the differences in tumour weight and LNM rate were analysed by one-way ANOVA, n = 12. ESCC, esophageal squamous cell carcinoma; miR-134, microRNA-134; ANOVA, analysis of variance; PLXNA1, plexin A1; NC, negative control; MLD, microlymphatic density; LNM, lymph node metastasis.

They provide the corrected Fig. 9 here to confirm. The findings of the paper are not affected by this error.